Nektar Therapeutics (NKTR) stock surged on Tuesday after the California-based biopharmaceutical company announced results from its Phase 2b study of rezpegaldesleukin. This is a treatment in development for patients with eczema.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Results from the clinical trial were positive, with the primary endpoint met. On top of that, all of the study’s secondary endpoints were also achieved. Nektar Therapeutics will continue treatment of patients in this study, with topline results expected in Q4 2025 and additional data in Q1 2026.
Nektar Therapeutics stock soared 110.17% on Tuesday alongside its clinical trial results. That builds on a 12.1% rally yesterday. However, the shares are still down 31.61% year-to-date and 40.56% over the past 12 months.
Is Nektar Therapeutics Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for Nektar Therapeutics is Strong Buy, based on four Buy and one Hold rating over the past three months. With that comes an average NKTR stock price target of $73.13, representing a potential 666.56% upside for the shares.
See more NKTR stock analyst ratings
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue